PTAB Cuts Down Two More Allergan Restasis Patents
The Patent Trial and Appeal Board has invalidated two patents on Allergan's dry-eye drug Restasis, delivering the potential final blow to a group of patents the drugmaker sought to shield from...To view the full article, register now.
Already a subscriber? Click here to view full article